Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% – What’s Next?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI)’s stock price was up 11.6% on Monday . The company traded as high as $25.92 and last traded at $25.76. Approximately 173,509 shares were traded during trading, an increase of 19% from the average daily volume of 145,659 shares. The stock had previously closed at $23.09.

Wall Street Analysts Forecast Growth

GLSI has been the topic of several research reports. HC Wainwright upped their price target on Greenwich LifeSciences from $39.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 30th. Wall Street Zen upgraded Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $47.50.

Greenwich LifeSciences Stock Down 1.4%

The firm’s 50-day moving average price is $26.00 and its two-hundred day moving average price is $16.06. The firm has a market capitalization of $367.99 million, a PE ratio of -18.20 and a beta of 1.50.

Insider Buying and Selling

In other news, CEO Snehal Patel acquired 4,300 shares of the stock in a transaction on Wednesday, December 31st. The shares were purchased at an average cost of $21.36 per share, for a total transaction of $91,848.00. Following the transaction, the chief executive officer owned 5,599,402 shares in the company, valued at approximately $119,603,226.72. This trade represents a 0.08% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have purchased 16,000 shares of company stock valued at $340,167. Company insiders own 51.47% of the company’s stock.

Institutional Trading of Greenwich LifeSciences

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Greenwich LifeSciences by 4.9% during the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after buying an additional 13,179 shares in the last quarter. Geode Capital Management LLC raised its position in Greenwich LifeSciences by 6.7% during the fourth quarter. Geode Capital Management LLC now owns 151,684 shares of the company’s stock valued at $3,187,000 after buying an additional 9,568 shares during the period. State Street Corp lifted its stake in Greenwich LifeSciences by 19.3% in the 4th quarter. State Street Corp now owns 97,777 shares of the company’s stock worth $2,054,000 after acquiring an additional 15,831 shares in the last quarter. Marshall Wace LLP acquired a new stake in Greenwich LifeSciences during the 2nd quarter worth about $509,000. Finally, Virtu Financial LLC acquired a new stake in Greenwich LifeSciences during the 4th quarter worth about $605,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.